Back to search

National and Kapodistrian University of Athens

Έκφραση της κυτταροκίνης οστεοποντίνης ως δείκτη φλεγμονής και ιστικής αναδιαμόρφωσης στο ήπιο / μέτριο και σοβαρό άσθμα: συσχέτιση με την κλινική βαρύτητα της νόσου, τις παροξύνσεις άσθματος και την αναδιαμόρφωση του βρογχικού ιστού

Abstract

dc:description

Introduction Asthma is a heterogeneous, chronic inflammatory disease of the lower airways characterized by increased airway hyper-responsiveness and reversible narrowing of the airways. A variety of mediators produced by several cells of the immune system as well as structural cells have been implicated in the pathogenesis of asthma, however the underlying mechanisms are not yet known. Osteopontin (Opn) is a cytokine typically associated with autoimmune and infectious responses. Recent studies have implicated Opn in allergic inflammation and airway remodeling in experimental animal models of asthma; however, its effects on human asthma are still unclear. Aim The primary aim of this study was to determine the expression pattern of Opn in the serum, bronchoalveolar lavage fluid (BALF) and bronchial and compare it to that of healthy controls, as well as to investigate whether Opn expression is dependent on asthma severity or the level of control of the disease. The secondary goal of this study was to identify the cellular sources of Opn production in situ in the bronchial tissue of patients with asthma. Finally, markers of airway remodeling were also assessed (reticular basement membrane thickness and goblet cell hyperplasia) in the bronchial tissue of patients with asthma in order to investigate possible correlations with tissue Opn expression. Methods A total of 71 subjects were included in the study, consisting of 54 patients with asthma and 17 controls. The patients group included 35 mild-moderate (MMA) and 19 severe asthma (SA) patients. The control group consisted of 17 non-smoking healthy individuals. Informed and written consent was obtained from all participating subjects and the corresponding protocol was approved by the Hospital Research Ethics Committee as well as the Greek National Organization for Medicines. Asthma severity was assessed according to GINA guidelines and patients were receiving treatment during the study according to their asthma severity. Serum samples were collected from all healthy controls and asthmatic patients in steady state, as well as from all patients that exhibited asthma exacerbations during the study (n=17). To evaluate the effect of steroids on Opn expression, serum samples were also obtained from 11 patients with moderate to severe asthma before and after 2 weeks of treatment with oral steroids. Flexible bronchoscopy was performed on 29 asthmatics (12 patients with mild-moderate and 17 with severe asthma) as well as on 9 healthy controls. Endobronchial biopsies were collected from all subjects that underwent bronchoscopy, while bronchoalveolar lavage fluid (BALF) was also obtained when possible. Opn levels were measured in the serum and BALF by means of Enzyme-linked immunosorbent assay (ELISA), while Opn expression in the bronchial tissue was determined by means of immunohistochemistry. Cells that expressed Opn in the bronchial tissue of asthmatic patients were identified by means of double immunofluorescence for Opn and specific cell markers for airway and vascular smooth muscle cells, myofibroblasts, T and B lymphocytes, mast cells, neutrophils and eosinophils. Double positive cells were visualized with the help of confocal laser microscopy. Reticular basement membrane (RBM) thickness and goblet cell hyperplasia were also determined in the bronchial tissue with the help of image analysis software. Results Serum Opn levels were significantly increased in patients with asthma in steady state, while Opn was significantly decreased in the serum of patients exhibiting exacerbations. BALF Opn levels were also significantly increased in asthmatic patients in steady state. No difference was found in both serum and BALF Opn levels between MMA and SA patients. Opn expression was significantly upregulated in the bronchial tissue of all patient groups compared to healthy controls in both the epithelium and subepithelial inflammatory infiltrating cells. Although no significant difference was found in Opn expression in the bronchial epithelium between MMA and SA patients, there was a trend for increased Opn expression in the SA group. However, SA patients had significantly increased Opn expression by the subepithelial inflammatory cells compared to MMA. Opn was found to be expressed by airway and vascular smooth muscle cells, myofibroblasts, T-lymphocytes and mast cells. RBM thickness was found to be increased in patients with asthma compared to healthy controls, while RBM thickness was more prominent in SA than MMA patients. Furthermore, Opn tissue expression correlated with RBM thickness. Goblet cells were increased in asthmatic patients compared to healthy controls. Although a trend for increased goblet cell numbers as asthma severity progressed, no significant difference was found between subgroups. Moreover, no correlation was found between goblet cell hyperplasia and Opn tissue expression. Conclusions The results of this study demonstrate that Opn expression in asthma is dependent upon asthma severity as well as the control status of the disease. Our data point to an active role for Opn in the development and regulation of airway inflammation and remodeling that is observed in human asthma and possibly open the way for research into future novel therapies that differentially target Opn expression in situ.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Samitas, Konstantinos
  • Σάμιτας, Κωνσταντίνος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/27224

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Samitas, Konstantinos; Σάμιτας, Κωνσταντίνος. Έκφραση της κυτταροκίνης οστεοποντίνης ως δείκτη φλεγμονής και ιστικής αναδιαμόρφωσης στο ήπιο / μέτριο και σοβαρό άσθμα: συσχέτιση με την κλινική βαρύτητα της νόσου, τις παροξύνσεις άσθματος και την αναδιαμόρφωση του βρογχικού ιστού. National and Kapodistrian University of Athens, 2011. http://hdl.handle.net/10442/hedi/27224